Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice

Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice

Abstract The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. These criteria offer objective measures for diagnosing and staging biological AD, bridging the ga...

Full description

Saved in:

Bibliographic Details
Main Authors:	Clifford R. Jack, Ana Graf, Samantha C. Burnham, Erin G Doty, Hans J. Moebius, Philip Montenigro, Eric Siemers, Kaycee M. Sink, Leslie M. Shaw, Charlotte Thim Hansen, Kristin R. Wildsmith, Simin Mahinrad, Maria C. Carrillo, Christopher J. Weber
Format:	Article
Language:	English
Published:	Wiley 2024-10-01
Series:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:	Alzheimer's disease biomarkers Alzheimer's disease diagnosis Alzheimer's disease imaging Alzheimer's disease staging Alzheimer's disease amyloid positron emission tomography
Online Access:	https://doi.org/10.1002/trc2.70013
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting
by: Ronald C. Petersen, et al.
Published: (2025-01-01)

Comparison of standardized uptake value ratio calculations in amyloid positron emission tomography brain imaging
by: Karin Knesaurek, et al.
Published: (2018-01-01)

New insight into the role of altered brain cholesterol metabolism in the pathogenesis of AD: A unifying cholesterol hypothesis and new therapeutic approach for AD
by: Xiaobo Yang, et al.
Published: (2025-05-01)

Phototherapy via Modulation of β‐Amyloid in Combating Alzheimer's Disease
by: Yunhua Zhang, et al.
Published: (2025-05-01)

From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias
by: Adalberto Studart-Neto, et al.
Published: (2022-08-01)

Combination therapy targeting Alzheimer's disease risk factors is associated with a significant delay in Alzheimer's disease–related cognitive decline
by: Yuan Shang, et al.
Published: (2025-01-01)

System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment
by: B. Joy Snider, et al.
Published: (2025-04-01)

Commentary on “Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer’s disease: A population-based study”
by: Feng Chen, et al.
Published: (2025-05-01)

How the use of FDG PET is improving the diagnosis of dementia in a reference center in Recife, Brazil
by: Luisa Couceiro de Albuquerque Macêdo, et al.
Published: (2025-05-01)

Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons
by: K. V. Shevtsova, et al.
Published: (2024-06-01)

Immune cell responses to amyloid-beta proteins: What is the extent and implications of amyloid-beta induced cytotoxicity in microglial cells and peripheral blood mononuclear cells?
by: Cao, A.
Published: (2017-07-01)

Beneficial Influence of Agomelatine Treatment on Behavioral Impairments in AΒ-Induced Rat Model of Alzheimer’s Disease
by: Kalina Ilieva, et al.
Published: (2020-12-01)

Alzheimer's disease and osteoporosis
by: Yu-Hung Chen, et al.
Published: (2017-01-01)

The effects of a bioavailable curcumin formulation on Alzheimer's disease pathologies: A potential risk for neuroinflammation
by: Shaun Cade, et al.
Published: (2024-12-01)

Diagnosis and Treatment of Alzheimer’s Disease: Current Update
by: Younghee Yim, et al.
Published: (2025-01-01)

IUPHAR review: From gut to brain: The role of gut dysbiosis, bacterial amyloids, and metabolic disease in Alzheimer’s disease
by: Saadet Inan, et al.
Published: (2025-05-01)

Spectrum of γ-Secretase dysfunction as a unifying predictor of ADAD age at onset across PSEN1, PSEN2 and APP causal genes
by: Sara Gutiérrez Fernández, et al.
Published: (2025-04-01)

Comparative Diagnostic Performance of Amyloid‐β Positron Emission Tomography and Magnetic Resonance Imaging in Alzheimer's Disease: A Head‐to‐Head Meta‐Analysis
by: Fang Li, et al.
Published: (2024-10-01)

Redefining disease in the age of blood-based biomarkers
by: Naveen K. Reddy
Published: (2025-02-01)

Prevalence of cerebral amyloid angiopathy and its correlation with Alzheimer's disease and cognition in an autopsy‐confirmed cohort from China
by: Xiang‐Sha Yin, et al.
Published: (2025-04-01)

Alzheimer's disease drug development pipeline: 2025
by: Jeffrey L. Cummings, et al.
Published: (2025-04-01)

Amyloid immunotherapy for Alzheimer's disease: the case for cautious adoption
by: Jonathan M. Schott, et al.
Published: (2025-05-01)

Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case report
by: Kirk C. Wilhelmsen, et al.
Published: (2024-06-01)

Accuracy of quantitative positron emission tomography assessment for differentiating cerebral age-related from pathological amyloid deposition: A preliminary report from a case-series study
by: Fulvio Lauretani, et al.
Published: (2018-04-01)

Survey among experts on the future role of tau‐PET in clinical practice and trials
by: Marie R. Vermeiren, et al.
Published: (2024-10-01)

Cerebrospinal Fluid Biomarkers of Alzheimer Disease
by: Kseniya V. Nevzorova, et al.
Published: (2025-06-01)

Synaptic markers are associated with cognitive decline after accounting for amyloid burden among an at-risk Alzheimer’s disease cohort
by: Elizabeth M. Planalp, et al.
Published: (2025-06-01)

Relationship of fasting glucose and longitudinal Alzheimer's disease imaging markers
by: Robyn A. Honea, et al.
Published: (2022-01-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-05-01)

A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research
by: Leonardo Iaccarino, et al.
Published: (2025-01-01)

Murine Non-Transgenic Models of Alzheimer’s Disease Pathology: Focus on Risk Factors
by: Maricarmen Hernández-Rodríguez, et al.
Published: (2025-03-01)

S100A8 Interaction with Amyloid-β Peptide Suppresses Its Fibrillation
by: Ekaterina Litus, et al.
Published: (2024-04-01)

Hyperphosphorylated tau-based Alzheimer’s Disease drug discovery: Identification of inhibitors of tau aggregation and cytotoxicity
by: Hsiao-Tien Hagar, et al.
Published: (2025-06-01)

Strategies for Treating Alzheimer’s: Current Approaches and Future Perspectives
by: Adriana Skuba, et al.
Published: (2025-05-01)

Cell-specific copper dyshomeostasis mechanism in Alzheimer’s disease
by: Michael Okafor, et al.
Published: (2025-08-01)

GABA Signaling in Spatial Memory changes in Animal Model of Alzheimer’s disease
by: Bahareh Tavakoli-Far, et al.
Published: (2024-08-01)

Targeted Magnetic Nanoparticles for Beta-Amyloid Detection
by: Nelly S. Chmelyuk, et al.
Published: (2024-10-01)

CD22 modulation alleviates amyloid β-induced neuroinflammation
by: Yu Dong Mai, et al.
Published: (2025-02-01)

Development of a novel radioiodinated compound for amyloid and tau deposition imaging in Alzheimer's disease and tauopathy mouse models
by: Xiyan Rui, et al.
Published: (2024-12-01)

Estimating the optimal cutoff for the IGT‐AD Distress subscale adapted for amyloid PET results disclosure
by: Dianxu Ren, et al.
Published: (2025-04-01)